26 Therapeutics is a preclinical-stage biotechnology company developing small-molecule therapies for dry eye disease and other meibomian gland disorders. The company's lead program is a topical, ...

Dry eye disease is a condition that afflicts millions of people worldwide, causing constant discomfort and affecting their quality of life. One of the key culprits behind this condition is meibomian ...

Please provide your email address to receive an email when new articles are posted on . LipiFlow has consistently demonstrated safety and efficacy in treating meibomian gland dysfunction. The review ...

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients reported reduced symptoms of dry eye for 12 ...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular ...

Dry eye disease is a common ocular condition that can significantly impair quality of life, and dysfunction of the meibomian glands is a major contributing factor. Advances in infrared meibography ...

You’ve probably never heard of Meibomian Gland Dysfunction. But chances are, you may experience it at some point in your life. It’s something 69 News reporter Jaccii Farris knows firsthand. Over the ...